Profile: Progenics Pharmaceuticals Inc (PGNX.OQ)
25 Apr 2017
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.
AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. AZEDRA has been granted breakthrough therapy and orphan drug designations, as well as Fast Track status in the United States and a Phase II registrational trial has been completed in patients with malignant and/or recurrent pheochromocytoma and paraganglioma. 1404 is a technetium-99m labeled small molecule, which binds PSMA and is used as an imaging agent to diagnose and detect localized prostate cancer, as well as soft tissue and bone metastases. It has completed a global multi-centered Phase II trial assessing the diagnostic accuracy of 1404 imaging in men with high-risk prostate cancer and a multi-center, open-label Phase III trial is ongoing to determine the sensitivity and specificity of 1404 to identify whether or not patients have clinically significant prostate cancer.
PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. A Phase II/III trial is commenced to assess the diagnostic performance of PyL PET/computed tomography (CT) imaging to detect prostate cancer in patients with recurrent and/or metastatic disease. 1095 is a PSMA-targeted Iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic. The PSMA TTC is designed to deliver a dose of alpha radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues.
RELISTOR is a treatment for opioid induced constipation (OIC) that addresses its underlying mechanism of OIC and decreases the constipating side effects induced by opioid pain medications, such as morphine and codeine without diminishing their ability to relieve pain. RELISTOR subcutaneous injection is approved and is being sold in the United States, European Union (E.U.) and Canada. Prostate cancer bone scan indexing products include Exini bone Bone scan index (BSI), which quantifies the hotspots on bone scans of prostate cancer patients and automatically calculates the BSI value, representing the disease burden of prostate cancer shown on the bone scan.
The Company competes with Nektar Therapeutics, AstraZeneca PLC, Merck & Co., Inc., Sucampo Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Aytu Bioscience Inc., Blue Earth Diagnostic, Inc., Johnson & Johnson, Medivation, Inc., Bayer HealthCare Pharmaceuticals Inc., Theravance, Inc. and Mundipharma International Limited.
Progenics Pharmaceuticals Inc
777 Old Saw Mill River Rd
TARRYTOWN NY 10591-6717
Company Web Links
- BRIEF-Progenics Pharmaceuticals announces positive topline results from registrational Phase 2B trial of Azedra®
- BRIEF-Progenics Pharmaceuticals posts Q4 loss per share $0.10
- BRIEF-Progenics Pharmaceuticals says initiation of Phase 1 clinical trial for metastatic prostate cancer treatment
- BRIEF-Progenics Pharma enters controlled equity offering sales agreement with Cantor Fitzgerald
- BRIEF-Progenics Pharmaceuticals files for mixed shelf of up to $250 mln - SEC filing